Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2025-10-23
ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmRCKT — Rocket Pharmaceuticals Inc
NASDAQ · Biotechnology · Biotechnology
$3.52+2.62%Market cap508.10M
- Latest Close
- $3.52
- 30-Day Move
- +2.6%
- Market Cap
- $508M
- Shares Outstanding
- 108,570,000
- P/B Ratio
- 1.37
- ROE
- -80.5%
NASDAQ:RCKTBiotechnology / BiotechnologyDelayed public snapshot
Rocket Pharmaceuticals Inc
A read-only Alphactor snapshot forRocket Pharmaceuticals Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$3.52
30-Day Move
+2.6%
Market Cap
$508M
Shares Outstanding
108,570,000
P/B Ratio
1.37
ROE
-80.5%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$3.52
+2.6%last 90 delayed daily bars
Market cap$508M
90D High
$5.45
90D Low
$3.00
Avg Volume
2,932,214
What stands out
RCKT is up 2.6% over the last 30 trading days shown on this page.
Latest operating income is $-44M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Dark Pool Short %
34.8%
Fundamentals snapshot
Latest Close
$3.52
30-Day Move
+2.6%
Market Cap
$508M
Shares Outstanding
108,570,000
P/B Ratio
1.37
ROE
-80.5%
ROA
-67.5%
Debt / Equity
0.08
Current Ratio
6.38
Latest Revenue
$0
Financial statement snapshot
Revenue
$0
Gross Profit
--
Operating Income
$-44M
Net Income
$-43M
Gross Margin
--
Net Margin
--
Current Ratio
6.38
Debt / Equity
0.08
Quality snapshot
Altman Z
-2.07
Distress
Piotroski
1
Weak (0-3)
Cash Conversion
0.85x
Rule of 40
--
Insufficient data
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-224M | $-222M | $-187M |
| 2023-12-31 | $0 | $-260M | $-246M | $-211M |
| 2024-12-31 | $0 | $-273M | $-259M | $-216M |
| 2025-12-31 | $0 | $-229M | $-223M | $-190M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2025-08-11
DEADLINE ALERT for RCKT, DDD, TEM, RDDT: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class ActionsPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2025-08-10
RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKTPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2025-08-08
Deadline Soon: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2025-08-07
MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$68,500
Sell Value
$466,809.33
Buys
2
Sells
34
Buy Value
$68,500
Sell Value
$466,809.33
Buy/Sell Ratio
0.06x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-18 | Militello John | Sell | 1,157 | $3.34 |
| 2026-02-18 | Shah Gaurav | Sell | 5,990 | $3.34 |
| 2026-02-18 | Wilson Martin | Sell | 1,376 | $3.34 |
| 2026-02-13 | Wilson Martin | Sell | 12,253 | $3.31 |
| 2026-02-13 | Militello John | Sell | 3,726 | $3.31 |
| 2026-02-13 | Shah Gaurav | Sell | 12,279 | $3.31 |
| 2026-02-11 | Shah Gaurav | A | 870,648 | $0.00 |
| 2026-02-11 | Shah Gaurav | A | 286,028 | $0.00 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2,730,210 | 0.03% | 2026-03-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2,700,288 | 0.02% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 2,041,440 | 0.02% | 2026-02-28 |
| Vanguard Explorer Fund | 1,221,308 | 0.01% | 2026-01-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 981,704 | 0.01% | 2025-12-31 |
| VANGUARD HORIZON FUNDS-Vanguard Strategic Equity Fund | 938,095 | 0.01% | 2025-12-31 |
| VANGUARD HORIZON FUNDS-Vanguard Strategic Small-Cap Equity Fund | 934,555 | 0.01% | 2025-12-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 822,374 | 0.01% | 2026-01-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Two Sigma Advisers
Filed 2025-05-15
--
--
BlackRock
Filed 2024-05-10
$160M
--
Vanguard Group
Filed 2025-05-09
$44M
+0.6%
Citadel Advisors
Filed 2025-05-15
$10M
--
D.E. Shaw
Filed 2026-02-17
$9M
+20.6%
Geode Capital Management
Filed 2026-02-09
$7M
+10.7%
Dark-pool activity snapshot
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.